title: Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.
abstract: BACKGROUND
  Immunohistochemistry (IHC) with mutation-specific antibodies may be an ancillary method of detecting EGFR mutations in lung cancer patients.
  
  
  METHODS
  EGFR mutation status was analyzed by DNA assays, and compared with IHC results in five non-small-cell lung cancer (NSCLC) cell lines and tumor samples from 78 stage IV NSCLC patients.
  
  
  RESULTS
  IHC correctly identified del 19 in the H1650 and PC9 cell lines, L858R in H1975, and wild-type EGFR in H460 and A549, as well as wild-type EGFR in tumor samples from 22 patients. IHC with the mAb against EGFR with del 19 was highly positive for the protein in all 17 patients with a 15-bp (ELREA) deletion in exon 19, whereas in patients with other deletions, IHC was weakly positive in 3 cases and negative in 9 cases. IHC with the mAb against the L858R mutation showed high positivity for the protein in 25/27 (93%) patients with exon 21 EGFR mutations (all with L858R) but did not identify the L861Q mutation in the remaining two patients.
  
  
  CONCLUSIONS
  IHC with mutation-specific mAbs against EGFR is a promising method for detecting EGFR mutations in NSCLC patients. However these mAbs should be validated with additional studies to clarify their possible role in routine clinical practice for screening EGFR mutations in NSCLC patients.
authors.affiliation: Pangaea Biotech, USP Dexeus University Institute, Barcelona, Spain.
authors.forename: Sara
authors.initials: S
authors.lastname: Simonetti
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Molina
authors.forename: Cristina
authors.initials: C
authors.lastname: Queralt
authors.forename: Itziar
authors.initials: I
authors.lastname: de Aguirre
authors.forename: Clara
authors.initials: C
authors.lastname: Mayo
authors.forename: Jordi
authors.initials: J
authors.lastname: Bertran-Alamillo
authors.forename: José Javier
authors.initials: JJ
authors.lastname: Sanchez
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Gonzalez-Larriba
authors.forename: Ulpiano
authors.initials: U
authors.lastname: Jimenez
authors.forename: Dolores
authors.initials: D
authors.lastname: Isla
authors.forename: Teresa
authors.initials: T
authors.lastname: Moran
authors.forename: Santiago
authors.initials: S
authors.lastname: Viteri
authors.forename: Carlos
authors.initials: C
authors.lastname: Camps
authors.forename: Rosario
authors.initials: R
authors.lastname: Garcia-Campelo
authors.forename: Bartomeu
authors.initials: B
authors.lastname: Massuti
authors.forename: Susana
authors.initials: S
authors.lastname: Benlloch
authors.forename: Santiago
authors.initials: S
authors.lastname: Ramon y Cajal
authors.forename: Miquel
authors.initials: M
authors.lastname: Taron
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm / Q000276:immunology*; D000918:Antibody Specificity / Q000276:immunology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000276:immunology* / Q000473:pathology; D045744:Cell Line, Tumor; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009367:Neoplasm Staging; D017384:Sequence Deletion
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D066246:ErbB Receptors